|
|
Post by liane on Jan 29, 2023 6:09:58 GMT -5
peppy - Very likely it is exactly the same drug - just dramatically cheaper in other countries than here.
|
|
|
|
Post by sayhey24 on Jan 29, 2023 8:40:04 GMT -5
I think a multi-prong approach looking at Afrezza-R, a "Treat To Target" study, etc. AFTER the kids and India studies are complete could just be the icing Mike is waiting for to possibly unlock offers from partners on the sidelines. Maybe I'm off-base with that inclination? The kids approval is nearly 2 years away. The India study is a redo of the Affinity 2. Maybe they added GLP1 to the study I hope but I don't know. Nudge can bring another approach which is pretty inexpensive for both afrezza-R and afrezza-T3 which are dosing studies which is what the FDA MIDD is all about. IDK, I would have these on deck if the the label gets "nudged" for approval. If MIDD accepts them for review how much risk is there? I guess it would be the consulting fee for Lane to write an algorithm and submission fees. You want to wait another 2 years to do what should have been done 8 years ago and then it will take 2-3 years in the study??? Why??? Mike would say he is balancing cash spent with other priorities and then spends on V-Go. What is the opportunity loss cost? Aged said just the GLP1s are bringing in over $40B. I would have Robert Ford on speed dial. Hopefully Mike does. Maybe I will call Mr. Ford myself and see what he says. Maybe he will say they have already talked. |
|
|
|
Post by sayhey24 on Jan 29, 2023 8:49:54 GMT -5
peppy - Very likely it is exactly the same drug - just dramatically cheaper in other countries than here. The prescription was for Amgen’s Amjevita which was not allowed to be sold in the US yet. It is next year after the patent protection runs out. |
|
|
|
Post by sportsrancho on Jan 29, 2023 17:17:48 GMT -5
So here we are in 2023 and we can see how the $35 Medicare cap is implemented. As expected (by me at least) it applies only to insulin currently in the insurer's formulary. In other words nothing changes except there is a $35 cap on the monthly bill. What has not happened is insurers being compelled to cover Afrezza because it is inhaled. Bingo! Now that we are nearly a month into the new year, I'd like to see credible evidence that ANY Seniors (or anyone else for that matter) are obtaining Afrezza for a monthly out-of-pocket cost of $35. Wish I was more optimistic on this issue, but I'm expecting .....crickets for at least the near term, but maybe it'll change later on. Sports, do you think any VDEX patients have only a $35 monthly copay for Afrezza? The poster has it right: if Afrezza is not on formulary, as is true for most plans then the $35 cap does not apply. I don’t see this program making a big difference bc of the way Afrezza is viewed (just another prandial insulin). As I’ve felt for years, there is an answer, a reset of that view, backed up with data that proves the case. ~Bill |
|
|
|
Post by sayhey24 on Jan 30, 2023 9:38:25 GMT -5
Bingo! Now that we are nearly a month into the new year, I'd like to see credible evidence that ANY Seniors (or anyone else for that matter) are obtaining Afrezza for a monthly out-of-pocket cost of $35. Wish I was more optimistic on this issue, but I'm expecting .....crickets for at least the near term, but maybe it'll change later on. Sports, do you think any VDEX patients have only a $35 monthly copay for Afrezza? The poster has it right: if Afrezza is not on formulary, as is true for most plans then the $35 cap does not apply. I don’t see this program making a big difference bc of the way Afrezza is viewed (just another prandial insulin). As I’ve felt for years, there is an answer, a reset of that view, backed up with data that proves the case. ~Bill I asked the opposite question which Blackbird asked - has anyone been denied Medicare which has gone through the pre auth process. Stevil stepped forward and said he had one from Humana but told us the other day afrezza Assist got involved and now they are approved. I think it would be great if it was on the formulary. When seniors go to Medicare.gov and they see huge money for afrezza its not even a consideration and they have no idea of the pre auth process. I also think the issue of the formulary was brought up by some just to try and "throw another bomb" at afrezza. I think your comment about afrezza being just another prandial insulin is the main issue. Why is that? Is it the way MNKD is presenting afrezza to the market? Kendall was sitting on a bunch of studies like the 118 study and others. More studies are great but we also need to have MNKD build on what they already have. |
|
|
|
Post by mango on Jan 30, 2023 11:44:47 GMT -5
I just took a look at the Afrezza HCP website and it’s even better than the last time I saw it.
At the very top is Ready. Set. Inhale
When subcutaneous (SC) rapid-acting insulins (RAIs) fail to keep pace…
Switch to the only ultra rapid-acting insulin that closely mimics physiologic insulin.1-4
As you scroll down it makes use of that ready set inhale line to tie it all together. Very nicely done.
|
|
|
|
Post by mango on Jan 30, 2023 11:50:14 GMT -5
I’d love for Mike to get back to the basics and start promoting Afrezza everywhere as the New Gold Standard. We need to re-educate the medical community about diabetes and what is proper for treating the underlying condition.
”Increasingly, evidence indicates that an early relatively rapid insulin response following glucose ingestion plays a critical role in the maintenance of postprandial glucose homeostasis. An early surge in insulin concentration can limit initial glucose excursions, mainly through the inhibition of endogenous glucose production. Therefore the induction of a rapid insulin response in a diabetic individual is expected to produce improved blood glucose homeostasis.”
That’s exactly what we see with Afrezza. The CGMs let us see.
|
|
